Adverse effects of tacrolimus in renal transplant patients from living donors

Current Drug Safety

Volumn 6, Issue 1, 2011, Pages 3-11

  Bulatova, Nailya ^a   Yousef, Al Motassem ^a   Al Khayyat, Ghada ^a   Qosa, Hisham ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Adverse effects; Immunosuppression; Kidney transplant; Living donors; Tacrolimus

Indexed keywords

AZATHIOPRINE; HEMOGLOBIN A1C; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ERYTHROCYTE COUNT; FEMALE; GRAFT RECIPIENT; HEADACHE; HIRSUTISM; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPONATREMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KAPOSI SARCOMA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LINEAR REGRESSION ANALYSIS; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; OBESITY; OBSERVATIONAL STUDY; PARESTHESIA; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; SEIZURE; SIDE EFFECT; SLEEP DEPRIVATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PREVALENCE; TACROLIMUS; YOUNG ADULT;

EID: 79551641003     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611794480043     Document Type: Article

References (44)

1. Wiesner RH. Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. Transplant Proc 1998; 30: 1399-400.
2. Tanabe K. Calcineurin inhibitors in renal transplantation: what is the best option? Drugs 2003; 63 (15): 1535-48.
3. Jain A, Reyes J, Kashyap R, et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. Transplant Proc 1998; 30: 1403-4.
4. Rabkin JM, Rosen HR, Corless CL, Olyaei AJ. Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients. Transplant Proc 2002; 34: 1557-8.
5. Loinaz C, Marin LM, Gonzalez-Pinto I, Gomez R, Jimenez C, Moreno E. A single-centre experience with cyclosporine microemulsion versus tacrolimus in 100 randomized liver transplant recipients: midterm efficacy and safety. Transplant Proc 2001; 33: 3439-41.
6. Levy G, Villamil F, Samuel D, et al. Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632-8.
7. Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003; 75: 1213-20.
8. Higgins R, Ramaiyan K, Dasgupta T, et al. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. Nephrol Dial Transplant 2004; 19: 444-50.
9. Pascual J, Ortuno J. Simple tacrolimus-based immunosuppressive regimens following renal transplantation: a large multicenter comparison between double and triple therapy. Transplant Proc 2002; 34: 89-91.
10. Daly TM, Kempe KC, Scott MG, et al. Bouncing creatinine levels [letter]. N Engl J Med 1996; 334: 1749-50.
11. Arms PA, Wedlund PJ, Branch RA. Adjustment of medications in liver failure. In: Chernow B, ed. The Pharmacologic Approach to the Critically Ill Patient. 2nd ed. Baltimore, MD: Williams & Wilkins, 1988; pp. 85-111.
12. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
13. American Diabetes Association. Standards of medical care in diabetes--2006. Diabetes Care 2006; 29 Suppl 1: S4-S42.
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
15. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158: 1855-67.
16. Pagana KD, Pagana TJ. Mosby's Diagnostic and Laboratory Test Reference, 6th ed. St. Louis, Missouri: Mosby, 2003.
17. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
18. Fukuhara N, Ono Y, Hattori R, et al. The long-term outcome of tacrolimus in cadaveric kidney transplantation from non-heart beating donors. Clin Transplant 2005; 19: 153-7.
19. Cheung CY, Wong KM, Chan HW, et al. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients. Transpl Int 2006; 19: 657-66.
20. Marcen R, Morales JM, del Castillo D, et al. Posttransplant diabetes mellitus in renal allograft recipients: A prospective multicenter study at 2 years. Transplant Proc 2006; 38: 3530-2.
21. Numakura K, Satoh S, Tsuchiya N, et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation 2005; 80: 1419-25.
22. Kamar N, Mariat C, Delahousse M, Lefrancois N, Dantal J, Benhamou P. New onset diabetes mellitus incidence and risk factors in kidney transplantation: results of the observational crosssectional study diapason. Transplant Proc 2006; 38: 2295-7.
23. Tricot L, Lebbe C, Pillebout E, Martinez F, Legendre C, Thervet E. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. Transplantation 2005; 80: 1546-9.
24. Caillard S, Agodoa LY, Bohen EM, Abbott KC. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006; 81: 888-95.
25. Rifai K, Kirchner GI, Bahr MJ, et al. A new side effect of immunosuppression: high incidence of hearing impairment after liver transplantation. Liver Transpl 2006; 12: 411-5.
26. Sekiguchi RT, Paixao CG, Saraiva L, Romito GA, Pannuti CM, Lotufo RF. Incidence of tacrolimus-induced gingival overgrowth in the absence of calcium channel blockers: a short-term study. J Clin Periodontol 2007; 34: 545-50.
27. Schwarz C, Benesch T, Kodras K, Oberbauer R, Haas M. Complete renal tubular acidosis late after kidney transplantation. Nephrol Dial Transplant 2006; 21: 2615-20.
28. Jensik SC. Tacrolimus (FK 506) in kidney transplantation: threeyear survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. Transplant Proc 1998; 30: 1216-8.
29. Sperschneider H. A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. Transplant Proc 2001; 33: 1279-81.
30. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006; 81: 845-52.
31. Schnitzler MA, Burroughs T, Takemoto SK. In: Gruesner RWG, Benedetti E. Living donor organ transplantation. McGraw Hill Companies, US. 2008; pp. 364-369.
32. Margreiter R, Pohanka E, Sparacino V, et al. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects. Transplant Int 2005; 18: 816-23.
33. Yoshizumi T, Taketomi A, Soejima Y, et al. Impact of donor age and recipient status on left-lobe graft for living donor adult liver transplantation. Transplant Int 2008; 21: 81-8.
34. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomized multicentre study. Lancet 2002; 359: 741-6.
35. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923-8.
36. CDC. Assessing risk factors for chronic disease--Jordan, 2004. Morb Mortal Wkly Rep 2006; 55: 653-5.
37. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206.
38. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-85.
39. Groetzner J, Meiser BM, Schirmer J, et al. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term followup? Transplant Proc 2001; 33: 1461-4.
40. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25: 583-92.
41. Mathew JT, Rao M, Job V, Ratnaswamy S, Jacob CK. Posttransplant hyperglycaemia: a study of risk factors. Nephrol Dial Transplant 2003; 18: 164-71.
42. Araki M, Flechner SM, Ismail HR, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006; 81: 335-41.
43. Ringe B, Braun F, Schutz E, et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001; 71: 508-15.
44. Gruessner RW, Sutherland DE, Drangstveit MB, Wrenshall L, Humar A, Gruessner AC. Mycophenolate mofetil in pancreas transplantation. Transplantation 1998; 66: 318-23.